(1R,3R)-1-(2,6-Difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-3-methyl-2-((3-methyloxetan-3-yl)methyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole

ID: ALA4867106

Chembl Id: CHEMBL4867106

PubChem CID: 121410563

Max Phase: Preclinical

Molecular Formula: C29H34F3N3O2

Molecular Weight: 513.60

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(OCCN3CC(CF)C3)cc2F)N1CC1(C)COC1

Standard InChI:  InChI=1S/C29H34F3N3O2/c1-18-9-22-21-5-3-4-6-25(21)33-27(22)28(35(18)15-29(2)16-36-17-29)26-23(31)10-20(11-24(26)32)37-8-7-34-13-19(12-30)14-34/h3-6,10-11,18-19,28,33H,7-9,12-17H2,1-2H3/t18-,28-/m1/s1

Standard InChI Key:  VFUSVPZBQWQXQH-KWMCUTETSA-N

Alternative Forms

  1. Parent:

    ALA4867106

    ---

Associated Targets(Human)

ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 513.60Molecular Weight (Monoisotopic): 513.2603AlogP: 5.10#Rotatable Bonds: 8
Polar Surface Area: 40.73Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 7.45CX LogP: 4.63CX LogD: 4.30
Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.46Np Likeness Score: -0.32

References

1. Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, Friedman LS, Gelzleichter T, Gill M, Giltnane JM, Goodacre S, Guan J, Hartman SJ, Ingalla ER, Kategaya L, Kiefer JR, Kleinheinz T, Labadie SS, Lai T, Li J, Liao J, Liu Z, Mody V, McLean N, Metcalfe C, Nannini MA, Oeh J, O'Rourke MG, Ortwine DF, Ran Y, Ray NC, Roussel F, Sambrone A, Sampath D, Schutt LK, Vinogradova M, Wai J, Wang T, Wertz IE, White JR, Yeap SK, Young A, Zhang B, Zheng X, Zhou W, Zhong Y, Wang X..  (2021)  GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,  64  (16.0): [PMID:34251202] [10.1021/acs.jmedchem.1c00847]

Source